TTA-A2

• Description :

  TTA-A2 is a potent, selective and orally active t-type voltage gated calcium channel antagonist with reduced pregnane X receptor (PXR) activation. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy[1][2].

• UNSPSC :

  12352005

• Target :

  Calcium Channel

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/tta-a2.html

• Concentration :

  10mM

• Purity :

  99.33

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(N[C@@H](C1=NC=C(OCC(F)(F)F)C=C1)C)CC2=CC=C(C3CC3)C=C2

• Molecular Formula :

  C20H21F3N2O2

• Molecular Weight :

  378.39

• References & Citations :

  [1]Thomas S Reger, et al.Pyridyl amides as potent inhibitors of T-type|[2]Richard L Kraus, et al.In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice. J Pharmacol Exp Ther. 2010 Nov;335 (2) :409-17.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  T-type calcium channel

• CAS Number :

  [953778-63-7]